featured
First-Line Pembrolizumab, Trastuzumab, and Doublet Chemotherapy for Advanced HER2-Positive Gastric Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Communications
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
Nat Commun 2022 Oct 12;13(1)6002, CK Lee, SY Rha, HS Kim, M Jung, B Kang, J Che, WS Kwon, S Park, WK Bae, DH Koo, SJ Shin, H Kim, HC Jeung, DY Zang, SK Lee, CM Nam, HC ChungFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.